EP0835119A1 - Fish oil and garlic nutritive composition - Google Patents

Fish oil and garlic nutritive composition

Info

Publication number
EP0835119A1
EP0835119A1 EP96921665A EP96921665A EP0835119A1 EP 0835119 A1 EP0835119 A1 EP 0835119A1 EP 96921665 A EP96921665 A EP 96921665A EP 96921665 A EP96921665 A EP 96921665A EP 0835119 A1 EP0835119 A1 EP 0835119A1
Authority
EP
European Patent Office
Prior art keywords
approximately
fish oil
garlic
capsaicin
rutin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96921665A
Other languages
German (de)
French (fr)
Other versions
EP0835119A4 (en
Inventor
Houn Simon Hsia
David Fan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viva America Marketing Inc
Original Assignee
Viva America Marketing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viva America Marketing Inc filed Critical Viva America Marketing Inc
Publication of EP0835119A1 publication Critical patent/EP0835119A1/en
Publication of EP0835119A4 publication Critical patent/EP0835119A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962Allium, e.g. garden onion, leek, garlic or chives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof

Definitions

  • the present invention provides a novel composition for preventing cardiovascular diseases in the human system, and more specifically to nutritive compositions containing fish oil, garlic, rutin, and capsaicin that reduce the levels of triglycerides, cholesterol, and low density lipoprotein (LDL) in the human blood serum, and increase the levels of high density lipoprotein (HDL) in human blood serum.
  • nutritive compositions containing fish oil, garlic, rutin, and capsaicin that reduce the levels of triglycerides, cholesterol, and low density lipoprotein (LDL) in the human blood serum, and increase the levels of high density lipoprotein (HDL) in human blood serum.
  • Cardiovascular disease resulting from the buildup of arterial plaque is known to be a leading cause of illness and death in humans.
  • Arterial plaque is caused by precipitous material formed chiefly of oxidized low density lipoprotein (0- LDL) .
  • the buildup of plaque in the form of O-LDL in the arteries is understood to be a factor in ischemic heart disease.
  • Free radical oxidants many of which come from naturally occurring sources such as sun exposure, metabolism of certain nutrients, exercise, or are otherwise often observed in persons suffering from diabetes and high blood pressure, act to oxidize LDL into its deleterious form, 0-LDL.
  • Free radical "scavengers" such as vitamins A, E, C, and selenium are believed to react with these oxidants and render them incapable of oxidation.
  • HDL high density lipoprotein
  • EFAs Essential fatty acids
  • EPA eicosapantaenoic acid
  • DHA docosahexaenoic acid
  • EFAs such as EPA and DHA are known precursors of eicosanoids -- a class of compounds which includes prostanoids such as prostaglandins and thromboxanes, leukotrienes, and hydroxy fatty acids. Eicosanoids are known are known to affect platelet aggregation, permeability and tone of the blood vessel walls, blood pressure, and inflammatory immune reactions. [Gerster, cited above] .
  • Glycogen storage disease is an inherited disorder, and is often complicated by severe hyperlipoproteinemia and hypercholesterolemia, which increase the risk of premature atherosclerosis and cardiovascular diseases. It has been reported that patients suffering from glycogen storage disease that received 10 grams of fish oil for 3 months experienced a significant decrease in levels of triglycerides in the blood serum (-49%) and cholesterol levels in the blood serum (-23%) , and a reduction in LDL levels in the blood serum (-40%) , and a significant increase in HDL levels in the blood serum (+30%). [Levy, E., et al. , I. Am. J. Clin. Nutr.. .57:922-29 (1993)] .
  • Garlic powder has been proposed to have a number of valuable benefits to the human body as a preventative against cardiovascular diseases. For example, daily ingestion of garlic leads to reduced levels of lipids in human blood serum, increased fibrinolysis and tissue plasminogen activator (t-PA) activity, and decreased plasma fibrogen viscosity, each of which may lessen the likelihood of cardiovascular disease.
  • t-PA tissue plasminogen activator
  • Flavonoids are secondary metabolites which are found in edible plants and foodstuffs derived from plants. Flavonoids are widely recognized as having antiallergic, anti-inflammatory, antiviral, antiproliferative and anticarcinogenic activities. [Manach, C, et al. J. Nutr. , 125:1911-22 (1995)]. Among flavonoids, flavonols occur most abundantly in plants as possess most of these biological properties. [Manach, cited above]. Flavonols naturally occur as O-glycides, typically having a sugar moiety bound at the C-3 position. Rutin is the principal glycoside form of quercetin, the most abundant flavonol in fruits and vegetables.
  • Capsaicin is a prominent chemical entity in plants of the Capsicum genus, which include chili peppers, red pepper, and paprika. Capsaicin is actually a class of compounds of branched- and straight-chain alkyl vanillylamides. The antimicrobial and analgesic properties of capsaicin have been known for centuries. In addition, capsaicin-containing products have been used to treat rheumatoid arthritis, osteoarthritis, diabetic neuropathy, postherpetic neuralgia, postmastectomy pain syndrome, cluster headache, and reflex sympathetic syndrome. [Cordell, G. and Araujo, 0. , Ann. Pharm.. 2_7:330-36 (1993)].
  • compositions used to reduce the risks of cardiovascular disease are known, the present invention comprises a novel combination of fish oil, garlic, rutin, and capsaicin, which achieve this purpose. As such, there remains a need in the art for novel compositions like those of the present invention which may be used to treat or prevent cardiovascular disease and disorders.
  • the present invention relates to the use of nutritional supplement compositions to overcome the nutritional deficiencies typically associated with the normal Western diet.
  • the compositions of the present invention are obtained by combining fish oil, garlic powder, rutin, and capsaicin.
  • the present invention relates to the daily co-administration of one preparation of fish oil, preferably as a single fish oil lozenge, and a preparation comprised of garlic powder, rutin, and capsaicin, preferably in a single lozenge.
  • compositions which will increase the levels of HDL in human blood serum. It is a further object of the invention to provide compositions which will decrease levels of O-LDL in human blood serum.
  • LDL should act to reduce the risk of heart disease in humans.
  • compositions of the present invention are aimed at reducing the rate of occurrence of heart disease and are comprised of: (1) fish oil; (2) garlic powder; (3) rutin; and (4) capsaicin. More specifically, the compositions of the present invention are a combination of a fish oil preparation, preferably in the form of a single fish oil lozenge, and a preparation comprised of garlic powder, rutin, and capsaicin, preferably in the form of a single lozenge which is co-administered with the fish oil lozenge.
  • the preferred weight of the fish oil lozenge is between about 500 mg and about 1500 mg, preferably about 1000 mg.
  • the preferred weight of the garlic lozenge is between about 400 mg and about 1000 mg, and most preferably about 700 mg.
  • the fish oil preparation component of the compositions of the present invention may be available from commercial sources. [Arista, Pharmachem] .
  • EPA and DHA are the active moieties of the fish oil preparation.
  • the fish oil preparation of the present invention comprises EPA in the amount of about 250 mg to about 350 mg, and most preferably about 300 mg.
  • the remainder of the fish oil preparation comprises from about 150 mg to about 250 mg of DHA, and preferably about 200 mg of DHA.
  • the total weight of the fish oil preparation of the present invention is from about 500 mg to about 1500 mg, and preferably about 1000 mg per fish oil lozenge when in the form of a single fish oil lozenge.
  • the garlic powder used in the garlic powder, rutin, and capsaicin preparation component of the compositions of the present invention may be obtained from commercially available sources. [Extracts, Ashland, Pure-Gar] .
  • a pharmaceutically acceptable form of garlic powder used in the compositions of the present invention comprises, by weight, from about 100 mg to about 700 mg, and more preferably about 175 mg to about 650 mg, and most preferably 500 mg of deodorized and aged garlic powder per garlic/rutin/capsaicin lozenge when in the form of a single lozenge.
  • the rutin which is employed in the garlic powder, rutin, and capsaicin preparation component of the compositions of the present invention may also be obtained from commercially available sources. [Westco Chemical, Freeman Industries, Inc.] .
  • the rutin component of the garlic powder, rutin, and capsaicin preparation comprised, by weight, from about 10 mg to about 150 mg, and most preferably about 100 mg.
  • Capsaicin which is used in the compositions of the present inventions may be commercially obtained. [AllChem, Good Hope Botanicals] .
  • the capsaicin component of the compositions of the present invention comprises, by weight, from about 20 mg to about 150 mg, and most preferably about 100 mg of capsaicin.
  • the garlic powder, rutin, and capsaicin components are admixed in the same preparation. This preparation is co- administered with the fish oil preparation -- the two preparations comprising the compositions of the present invention. These preparations may be made by conventional methods.
  • compositions of the invention are combined as the active ingredient in intimate admixture with a suitable carrier according to conventional compounding techniques.
  • This carrier may take a wide variety of forms depending upon the form of preparation desired for administration, e.g., oral, sublingual, nasal, or parenteral.
  • any of the usual pharmaceutical media may be employed.
  • oral liquid preparations e.g., suspensions, elixirs, and solutions
  • media containing for example, water, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used.
  • Carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to prepare oral - solids (e.g., powders, capsules, pills, tablets, and lozenges) .
  • Lozenges are a preferred oral dosage form. Controlled release forms may also be used.
  • lozenges, tablets, pills, and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
  • tablets may be sugar coated or enteric coated by standard techniques.
  • additional inactive components which provide for easier oral administration include but are not limited to lemon bioflavonoids [Botanical International, Freeman], parsley powder, d-alpha tocopherol, bee's wax, lecithin, gelatin, purified water, and glycerin. These compounds may be used in creating the lozenges of the novel nutritional supplements.
  • the carrier will usually comprise sterile water, although other ingredients may be included, e.g., to aid solubility or for preservation purposes.
  • injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be employed.
  • a preferred method for using the present invention is for the user to ingest, daily from about 4 to 8 lozenges of the fish oil preparation, most preferably about 6 lozenges of the fish oil preparation, together with from about 3 to 5 lozenges of the garlic powder, capsaicin and rutin preparation, and most preferably 4 lozenges of the garlic powder, capsaicin and rutin preparation.
  • the following examples illustrate the preferred embodiments of the present invention. These examples are illustrative only, and do not purport to limit the invention in any fashion.
  • EXAMPLE 1 The effect of the present invention on the human lipid profile was measured. A double blind study carried out at the University of California at Irvine Medical School showed that the proper use of the present invention provides for the following effects in human blood serum: (1) a significant reduction in triglyceride levels; (2) a significant decrease in cholesterol and LDL; and (3) a significant increase in the levels of HDL.
  • the protocol followed during this investigation was as follows. Ten subjects participated in a month-long study wherein each subject ingested ten lozenges for each day of the study.
  • the placebo group used 10 nonactive lozenges each day for one month, and the active group ingested 10 lozenges of the present invention each day for one month.
  • EXAMPLE 2 The following example provides a preferred composition of the present invention.
  • the composition is provided as two separate preparations: lozenge A (fish oil) and lozenge B (garlic, capsaicin, and rutin) .
  • the proper daily dosage is six of lozenge A and four of lozenge B (in other words, three of lozenge A and two of lozenge B taken twice daily for a total of ten lozenges) .
  • the following example provides a preferred composition of the present invention.
  • the composition is provided as two separate preparations: Lozenge A (fish oil) and Lozenge B (garlic, capsaicin, rutin) .
  • the proper dosage is six capsules of Lozenge A each day and four capsules of Lozenge B (in other words, three of lozenge A and two of lozenge B taken twice daily for a total of ten lozenges) .
  • EXAMPLE 4 The following example provides a preferred composition of the present invention.
  • the composition is provided as a single preparation.
  • the proper dosage is five capsules of the lozenge taken twice each day.

Abstract

The present invention relates to nutritional supplements to the human diet used to increase levels of HDL, and decrease levels of O-LDL, cholesterol, and triglycerides in human blood plasma. More specifically, the present invention teaches a novel nutritional supplements which contain a novel combination of fish oil, garlic, rutin, and capsaicin, as well as methods of preparing the nutritional supplements.

Description

FISH OIL AND GARLIC NUTRITIVE COMPOSITION
Cross-Reference to Related Application
This is a continuation-in-part of co-pending provisional application Ser. No. , filed March 12, 1996.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention provides a novel composition for preventing cardiovascular diseases in the human system, and more specifically to nutritive compositions containing fish oil, garlic, rutin, and capsaicin that reduce the levels of triglycerides, cholesterol, and low density lipoprotein (LDL) in the human blood serum, and increase the levels of high density lipoprotein (HDL) in human blood serum.
2. Background of the Invention In the last few years, scientific literature has provided strong evidence for a bona fide link between micronutrient compositions (such as vitamins, minerals, fish oils, and plant extracts) and cardiovascular disease. For humans of high risk for cardiovascular diseases, realizing an appreciable reduction in the levels of high cholesterol, triglycerides, low density lipoprotein (LDL) in their blood serum is known to be important for reducing the risk of cardiac diseases. It is also known that effecting an increase in the levels of high density lipoprotein (HDL) also provides a significant decrease to the risk of cardiac diseases.
Cardiovascular disease resulting from the buildup of arterial plaque is known to be a leading cause of illness and death in humans. Arterial plaque is caused by precipitous material formed chiefly of oxidized low density lipoprotein (0- LDL) . The buildup of plaque in the form of O-LDL in the arteries is understood to be a factor in ischemic heart disease. Free radical oxidants, many of which come from naturally occurring sources such as sun exposure, metabolism of certain nutrients, exercise, or are otherwise often observed in persons suffering from diabetes and high blood pressure, act to oxidize LDL into its deleterious form, 0-LDL. Free radical "scavengers" such as vitamins A, E, C, and selenium are believed to react with these oxidants and render them incapable of oxidation. The inhibitory action of these antioxidants thus inhibits the formation of O- LDL, thereby lowering the levels of arterial plaque deposits in blood vessels. In contrast, the presence of high density lipoprotein (HDL) in the body is understood to have beneficial health effects. Specifically, HDL is known to be a more soluble form of lipoprotein, hence its presence does not significantly contribute to the formation of arterial plaque. In addition, it is known that HDL is able to absorb plaque material and may thus directly reduce the amount of arterial plaque.
3. Description of Prior Art
Essential fatty acids (EFAs) are naturally occurring unsaturated fatty acids with a chain length of 18, 20, or 22 carbon atoms. These EFAs cannot be synthesized by the body, hence, dietary intake of EFAs is required. Two fatty acids which fall within the family of EFAs are eicosapantaenoic acid (EPA) and docosahexaenoic acid (DHA) , both of which are commonly found in fish oils. Epidemiological observations indicate that fish oils reduce platelet aggregation and serum triglycerides which may reduce the risk of myocardial infarction, hypertension, atherosclerosis, and certain types of cancer. [Gerster, H., Internat. J. Vit. Nutr. Res.. 6_5_:3-20 (1994)] . Specifically, it has been shown that EPA and DHA derived from fish oils play important structural roles in membranes of most cells, and influence the fluidity of the cell membranes as expressed by decreased whole-blood viscosity and increased erythrocyte flexibility and deformability [Gerster, cited above] . In addition, EFAs such as EPA and DHA are known precursors of eicosanoids -- a class of compounds which includes prostanoids such as prostaglandins and thromboxanes, leukotrienes, and hydroxy fatty acids. Eicosanoids are known are known to affect platelet aggregation, permeability and tone of the blood vessel walls, blood pressure, and inflammatory immune reactions. [Gerster, cited above] .
Fish oil dietary supplementation is known to have other beneficial health effects. Glycogen storage disease is an inherited disorder, and is often complicated by severe hyperlipoproteinemia and hypercholesterolemia, which increase the risk of premature atherosclerosis and cardiovascular diseases. It has been reported that patients suffering from glycogen storage disease that received 10 grams of fish oil for 3 months experienced a significant decrease in levels of triglycerides in the blood serum (-49%) and cholesterol levels in the blood serum (-23%) , and a reduction in LDL levels in the blood serum (-40%) , and a significant increase in HDL levels in the blood serum (+30%). [Levy, E., et al. , I. Am. J. Clin. Nutr.. .57:922-29 (1993)] .
Garlic powder has been proposed to have a number of valuable benefits to the human body as a preventative against cardiovascular diseases. For example, daily ingestion of garlic leads to reduced levels of lipids in human blood serum, increased fibrinolysis and tissue plasminogen activator (t-PA) activity, and decreased plasma fibrogen viscosity, each of which may lessen the likelihood of cardiovascular disease. [Brosche, T. et al. , British J. Clin. Practice, Supp. 69:12-19 (1990) ; Kiesewetter H. et al., British J. Clin. Practice. SUPP. 69:24-29 (1990)]. In addition, the daily ingestion of garlic is known to reduce the total levels of cholesterol and triglycerides in human serum, as well as reduce blood pressure peripheral vasodilation. [Auer, . et al., British J. Clin. Practice. SUPP. 69:3-6 (1990)] .
Flavonoids are secondary metabolites which are found in edible plants and foodstuffs derived from plants. Flavonoids are widely recognized as having antiallergic, anti-inflammatory, antiviral, antiproliferative and anticarcinogenic activities. [Manach, C, et al. J. Nutr. , 125:1911-22 (1995)]. Among flavonoids, flavonols occur most abundantly in plants as possess most of these biological properties. [Manach, cited above]. Flavonols naturally occur as O-glycides, typically having a sugar moiety bound at the C-3 position. Rutin is the principal glycoside form of quercetin, the most abundant flavonol in fruits and vegetables.
Capsaicin is a prominent chemical entity in plants of the Capsicum genus, which include chili peppers, red pepper, and paprika. Capsaicin is actually a class of compounds of branched- and straight-chain alkyl vanillylamides. The antimicrobial and analgesic properties of capsaicin have been known for centuries. In addition, capsaicin-containing products have been used to treat rheumatoid arthritis, osteoarthritis, diabetic neuropathy, postherpetic neuralgia, postmastectomy pain syndrome, cluster headache, and reflex sympathetic syndrome. [Cordell, G. and Araujo, 0. , Ann. Pharm.. 2_7:330-36 (1993)].
Although compositions used to reduce the risks of cardiovascular disease are known, the present invention comprises a novel combination of fish oil, garlic, rutin, and capsaicin, which achieve this purpose. As such, there remains a need in the art for novel compositions like those of the present invention which may be used to treat or prevent cardiovascular disease and disorders.
SUMMARY OF THE INVENTION
The present invention relates to the use of nutritional supplement compositions to overcome the nutritional deficiencies typically associated with the normal Western diet. The compositions of the present invention are obtained by combining fish oil, garlic powder, rutin, and capsaicin. Specifically, the present invention relates to the daily co-administration of one preparation of fish oil, preferably as a single fish oil lozenge, and a preparation comprised of garlic powder, rutin, and capsaicin, preferably in a single lozenge.
It is therefore an object of the invention to provide nutritious and safe compositions for human consumption as dietary supplements that contain fish oil, garlic powder, rutin, and capsaicin.
It is another object to provide novel compositions which will increase the levels of HDL in human blood serum. It is a further object of the invention to provide compositions which will decrease levels of O-LDL in human blood serum.
It is still another object of the invention to provide compositions which will reduce the levels of cholesterol and triglycerides in human blood serum.
The increase of HDL and the reduction of cholesterol and O-
LDL should act to reduce the risk of heart disease in humans.
Therefore, it is another object of the present invention to provide for the reduction of the risk of cardiovascular disease by daily administration of the compositions of the invention.
DETAILED DESCRIPTION OF THE INVENTION
Daily doses of the compositions of the present invention are aimed at reducing the rate of occurrence of heart disease and are comprised of: (1) fish oil; (2) garlic powder; (3) rutin; and (4) capsaicin. More specifically, the compositions of the present invention are a combination of a fish oil preparation, preferably in the form of a single fish oil lozenge, and a preparation comprised of garlic powder, rutin, and capsaicin, preferably in the form of a single lozenge which is co-administered with the fish oil lozenge. The preferred weight of the fish oil lozenge is between about 500 mg and about 1500 mg, preferably about 1000 mg. The preferred weight of the garlic lozenge is between about 400 mg and about 1000 mg, and most preferably about 700 mg.
The fish oil preparation component of the compositions of the present invention may be available from commercial sources. [Arista, Pharmachem] . EPA and DHA are the active moieties of the fish oil preparation. The fish oil preparation of the present invention comprises EPA in the amount of about 250 mg to about 350 mg, and most preferably about 300 mg. The remainder of the fish oil preparation comprises from about 150 mg to about 250 mg of DHA, and preferably about 200 mg of DHA. The total weight of the fish oil preparation of the present invention is from about 500 mg to about 1500 mg, and preferably about 1000 mg per fish oil lozenge when in the form of a single fish oil lozenge.
The garlic powder used in the garlic powder, rutin, and capsaicin preparation component of the compositions of the present invention may be obtained from commercially available sources. [Extracts, Ashland, Pure-Gar] . In addition, it is preferable to use a deodorized and aged form of garlic powder. A pharmaceutically acceptable form of garlic powder used in the compositions of the present invention comprises, by weight, from about 100 mg to about 700 mg, and more preferably about 175 mg to about 650 mg, and most preferably 500 mg of deodorized and aged garlic powder per garlic/rutin/capsaicin lozenge when in the form of a single lozenge.
The rutin which is employed in the garlic powder, rutin, and capsaicin preparation component of the compositions of the present invention may also be obtained from commercially available sources. [Westco Chemical, Freeman Industries, Inc.] . The rutin component of the garlic powder, rutin, and capsaicin preparation comprised, by weight, from about 10 mg to about 150 mg, and most preferably about 100 mg.
Capsaicin which is used in the compositions of the present inventions may be commercially obtained. [AllChem, Good Hope Botanicals] . When employed in the garlic powder, rutin, capsaicin preparation of the present invention, the capsaicin component of the compositions of the present invention comprises, by weight, from about 20 mg to about 150 mg, and most preferably about 100 mg of capsaicin. The garlic powder, rutin, and capsaicin components are admixed in the same preparation. This preparation is co- administered with the fish oil preparation -- the two preparations comprising the compositions of the present invention. These preparations may be made by conventional methods. To prepare the compositions of the invention, the above-described fish oil and garlic powder/rutin/capsaicin preparations are combined as the active ingredient in intimate admixture with a suitable carrier according to conventional compounding techniques. This carrier may take a wide variety of forms depending upon the form of preparation desired for administration, e.g., oral, sublingual, nasal, or parenteral.
In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. For oral liquid preparations (e.g., suspensions, elixirs, and solutions), media containing for example, water, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used. Carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to prepare oral - solids (e.g., powders, capsules, pills, tablets, and lozenges) . Lozenges are a preferred oral dosage form. Controlled release forms may also be used. Because of their ease in administration, lozenges, tablets, pills, and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. Examples of these additional inactive components which provide for easier oral administration include but are not limited to lemon bioflavonoids [Botanical International, Freeman], parsley powder, d-alpha tocopherol, bee's wax, lecithin, gelatin, purified water, and glycerin. These compounds may be used in creating the lozenges of the novel nutritional supplements.
For parenteral products, the carrier will usually comprise sterile water, although other ingredients may be included, e.g., to aid solubility or for preservation purposes. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be employed.
A preferred method for using the present invention is for the user to ingest, daily from about 4 to 8 lozenges of the fish oil preparation, most preferably about 6 lozenges of the fish oil preparation, together with from about 3 to 5 lozenges of the garlic powder, capsaicin and rutin preparation, and most preferably 4 lozenges of the garlic powder, capsaicin and rutin preparation. The following examples illustrate the preferred embodiments of the present invention. These examples are illustrative only, and do not purport to limit the invention in any fashion.
EXAMPLE 1 The effect of the present invention on the human lipid profile was measured. A double blind study carried out at the University of California at Irvine Medical School showed that the proper use of the present invention provides for the following effects in human blood serum: (1) a significant reduction in triglyceride levels; (2) a significant decrease in cholesterol and LDL; and (3) a significant increase in the levels of HDL.
The protocol followed during this investigation was as follows. Ten subjects participated in a month-long study wherein each subject ingested ten lozenges for each day of the study. The placebo group used 10 nonactive lozenges each day for one month, and the active group ingested 10 lozenges of the present invention each day for one month. Each subject ingested three fish oil lozenges and two garlic powder/rutin/capsaicin lozenges
(twice daily) for a total daily ingestion of ten lozenges. The identity of the lozenge was unknown by the subjects, and to the examiner (i.e., a double blind study). Blood serum
(approximately 4 cc) was collected at the starting time and again after the completion of one month of usage. A fasting lipid profile was conducted on the plasma samples using a lipid fractionation panel automated system. [Hewlett-Packard Co.] .
In addition, measurements of electrolytes (including calcium ion) and glucose levels were made using the Chem 18 automated system. [Hewlett-Packard Co.] . The results were compared using statistical analytical methods and are shown in the attached Figure 1.
These results demonstrate a reduction in plasma triglyceride concentration of 41% in comparison to the placebo. In addition, the cholesterol levels showed a 9% reduction, the LDL levels showed a 7% reduction, and the HDL levels showed a 17% increase.
These data provide the basis for evaluating the effectiveness of the present invention in causing an increase in human serum HDL levels and a decrease in the levels of serum cholesterol, triglycerides, and low density lipoprotein (LDL) .
EXAMPLE 2 The following example provides a preferred composition of the present invention. The composition is provided as two separate preparations: lozenge A (fish oil) and lozenge B (garlic, capsaicin, and rutin) . The proper daily dosage is six of lozenge A and four of lozenge B (in other words, three of lozenge A and two of lozenge B taken twice daily for a total of ten lozenges) .
Ingredient Weight
Lozenge A 1000 mg
Fish Oil 1000 mg
Lozenge B 700 mg
Garlic Powder 487 mg Capsaicin 53 mg
Rutin 27 mg lemon bioflavonoid 23 mg parsley powder 110 mg EXAMPLE 3 The following example provides a preferred composition of the present invention. The composition is provided as two separate preparations: Lozenge A (fish oil) and Lozenge B (garlic, capsaicin, rutin) . The proper dosage is six capsules of Lozenge A each day and four capsules of Lozenge B (in other words, three of lozenge A and two of lozenge B taken twice daily for a total of ten lozenges) .
Ingredient Weight
Lozenge A 950 mg
Fish Oil 950 mg
Lozenge B 700 mg
Garlic Powder 600 mg
Capsaicin 50 mg
Rutin 50 mg
EXAMPLE 4 The following example provides a preferred composition of the present invention. The composition is provided as a single preparation. The proper dosage is five capsules of the lozenge taken twice each day.
Ingredient Weight fish oil* 570 mg garlic powder 194 mg rutin 11 mg capsaicin 21 mg lemon bioflavonoids 11 mg parsley powder 38 mg d-alpha tocopherol 5 mg bee' s wax 75 mg lecithin 75 mg gelatin 255 mg purified water 10 mg glycerin 170 mg fish oil in the form of 300:200 of EPA:DHA Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. It is also intended that the present invention cover modifications and variations of the compositions and method for using them to accomplish their claimed uses within the scope of the appended claims and their equivalents.

Claims

WE CLAIM :
1. A nutritional supplement comprising fish oil, garlic, rutin, and capsaicin.
2. The nutritional supplement of claim 1, wherein the fish oil is in the form of a single fish oil lozenge.
3. The nutritional supplement of claim 2, wherein the garlic, rutin, and capsaicin are in the form of a single garlic, rutin, and capsaicin lozenge.
4. The nutritional supplement of claim 1, wherein the fish oil, garlic, rutin, and capsaicin are in the form of a single lozenge.
5. The nutritional supplement of claim 3, wherein the fish oil lozenge is between approximately 350 mg to approximately 650 mg.
6. The nutritional supplement of claim 5, wherein the fish oil lozenge is approximately 500 mg.
7. The nutritional supplement of claim 3, wherein the garlic is between approximately 200 mg to approximately 700 mg, the rutin is between approximately 10 mg to approximately 150 mg, and the capsaicin is between approximately 20 mg to approximately 150 mg.
8. The nutritional supplement of claim 7, wherein the fish oil is approximately 500 mg, the garlic is approximately 500 mg, the rutin is approximately 100 mg, and the capsaicin is approximately 100 mg.
9. The nutritional supplement of claim 7, wherein the fish oil is approximately 500 mg, the garlic is approximately 275 mg, the rutin is approximately 135 mg, and the capsaicin is approximately 90 mg.
10. The nutritional supplement of claim 7, wherein the fish oil is approximately 600 mg, the garlic is approximately 200 mg, the rutin is approximately 10 mg, and the capsaicin is approximately 20 mg.
11. The nutritional supplement of claim 3, wherein the garlic, rutin, and capsaicin lozenge is between approximately 350 mg and approximately 650 mg.
12. The nutritional supplement of claim 7, wherein the garlic, rutin, and capsaicin lozenge is approximately 500 mg.
13. The nutritional supplement of claim 3, wherein the total weight of the fish oil and garlic, rutin, and capsaicin lozenges is between approximately 700 mg and approximately 1,300 mg.
14. The nutritional supplement of claim 13, wherein the total weight of the fish oil and garlic, rutin, and capsaicin lozenges is approximately 1,000 mg.
15. The nutritional supplement of claim 1, wherein the fish oil comprises between approximately 250 IU to approximately 350 IU EPA.
16. The nutritional supplement of claim 15, wherein the fish oil comprises approximately 300 IU EPA.
17. The nutritional supplement of claim 1, wherein the fish oil comprises between approximately 150 IU to approximately 250 IU DHA.
18. The nutritional supplement of claim 17, wherein the fish oil comprises approximately 200 IU DHA.
19. The nutritional supplement of claim 1, wherein the garlic is in the form of garlic powder.
20. A method of preparing the nutritional supplement of the present invention comprising admixing the fish oil, garlic, rutin, and capsaicin components with a suitable carrier.
21. A method of increasing the levels of HDL in human blood plasma comprising administering daily the nutritional supplement of claim 3 or claim 4.
22. A method of decreasing the levels of O-LDL, cholesterol, and triglycerides in human blood plasma comprising administering daily the nutritional supplement of claim 3 or claim 4.
23. The method of claim 21, wherein the daily dosage is comprised of from approximately 4 to approximately 8 fish oil lozenges together with from approximately 3 to approximately 5 garlic, rutin, and capsaicin lozenges.
24. The method of claim 22, wherein the daily dosage is comprised of from approximately 4 to approximately 8 fish oil lozenges together with from approximately 3 to approximately 5 garlic, rutin, and capsaicin lozenges.
25. The method of claim 23 or claim 24, wherein the daily dosage is comprised of approximately 6 fish oil lozenges together with approximately 4 garlic, rutin, and capsaicin lozenges.
EP96921665A 1996-03-12 1996-06-17 Fish oil and garlic nutritive composition Withdrawn EP0835119A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2517396P 1996-03-12 1996-03-12
PCT/US1996/010500 WO1997033599A1 (en) 1996-03-12 1996-06-17 Fish oil and garlic nutritive composition
US25173 2001-12-19

Publications (2)

Publication Number Publication Date
EP0835119A1 true EP0835119A1 (en) 1998-04-15
EP0835119A4 EP0835119A4 (en) 1998-08-26

Family

ID=21824477

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96921665A Withdrawn EP0835119A4 (en) 1996-03-12 1996-06-17 Fish oil and garlic nutritive composition

Country Status (4)

Country Link
EP (1) EP0835119A4 (en)
CN (1) CN1190347A (en)
AU (1) AU6282796A (en)
WO (1) WO1997033599A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000019717A (en) * 1998-09-15 2000-04-15 박호군 Composition comprising rutin and quercetin for preventing and treating hyperlipidemia, arteriosclerosis and liver disease
KR20030080340A (en) * 2002-04-08 2003-10-17 주식회사 엔바이오제네시스 Manufacture method of diet food involving capsicin
FR2849992B1 (en) 2003-01-17 2007-03-16 Inst Phytoceutic COMPOSITION FOR ORAL ADMINISTRATION CONTAINING CAPSAICINOIDS
CN101103966B (en) * 2006-07-14 2010-11-03 上海展望科技有限公司 Omega-3 falty acid-garlic oil capsule and manufacturing method thereof
DE502006004193D1 (en) * 2006-09-19 2009-08-20 Schrezenmeir Juergen Sabal fruits or Sabal oil as lipase inhibitor
CN104208454A (en) * 2014-06-30 2014-12-17 江苏伟楼生物科技有限公司 Garlic oil softgel and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1148206B (en) * 1963-12-23 1986-11-26 Medicinali D U R S T Srl Fab Rutine vitamin e deriv complexes
DE3520761A1 (en) * 1984-06-11 1985-12-12 Ajinomoto Co., Inc., Tokio/Tokyo USE OF VANILLYLAMINE OR VANILLYLAMIDES TO PROMOTE FAT METABOLISM
JPS6211079A (en) * 1985-07-08 1987-01-20 Nobutsugu Kimura Compounded food good for blood vessel system
JPH0817673B2 (en) * 1991-08-06 1996-02-28 卓蔵 松山 Activated garlic paste, method for producing the same, and foods using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 8708 Derwent Publications Ltd., London, GB; Class D12, AN 87-054239 XP002058837 & JP 62 011 079 A (KIMURA N) , 20 January 1987 *
DATABASE WPI Section Ch, Week 9344 Derwent Publications Ltd., London, GB; Class D13, AN 93-347529 XP002058838 & JP 05 252 893 A (MATSUYAMA T) , 5 October 1993 *
See also references of WO9733599A1 *

Also Published As

Publication number Publication date
EP0835119A4 (en) 1998-08-26
CN1190347A (en) 1998-08-12
WO1997033599A1 (en) 1997-09-18
AU6282796A (en) 1997-10-01

Similar Documents

Publication Publication Date Title
US6326031B1 (en) Method of decreasing cholesterol and triglycerides levels with a composition containing fish oil, garlic, rutin, and capsaicin
US6440464B1 (en) Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
US6054128A (en) Dietary supplements for the cardiovascular system
US5976548A (en) Nutritional supplement composition and use
EP0265046B1 (en) Balanced fiber composition
US20050233944A1 (en) Arginine compositions for coordinate modification of multiple cardiovascular risk factors
WO2001049285A1 (en) Flavonoid drug and dosage form, its production and use
KR102038810B1 (en) Growth hormone secretion promoter
JP2008297209A (en) Lipid metabolism-improving composition
JP3768795B2 (en) Xanthine oxidase inhibitor
JPH11246399A (en) Lipid metabolism improving composition
US20190134165A1 (en) Compositions and methods for treating thyroid disease
JP2004321171A (en) Food and drink
WO1997033599A1 (en) Fish oil and garlic nutritive composition
WO1998000024A1 (en) Nutritional supplement composition and use
KR20160128953A (en) Composition for prevention or treatment of blood circulation disorders or metabolic disorders comprising an Persimmon leaf extract
US8263137B2 (en) Nutritional supplement for women
US6506420B2 (en) Combinations of psyllium and chitosan for synergistic adsorption of triglyceride
WO2022013581A1 (en) Nutritional supplement, suitable for oral administration, comprising dihydromyricetin, choline and one or more vitamins with antioxidant activity, for use in the maintenance of normal liver function
WO2007121584A1 (en) Food product containing policosanols
Silverman Jr et al. Clinical and lymphocyte responses to beta-carotene supplementation in 11 HIV-positive patients with chronic oral candidiasis
US6787162B1 (en) Method and composition for regulation of blood cholesterol
RU2033732C1 (en) Foodstuff
KR20010026440A (en) Composition for alcohol-detoxification
RU2351350C1 (en) Set "predstar", its application and method of prevention of premature organism aging

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19980305

A4 Supplementary search report drawn up and despatched

Effective date: 19980713

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010103